NAV
$99.12
AUM
$77.9M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.79
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +24.76% | +17.70% | +19.12% | +68.87% | +23.54% | +13.04% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | IBRX | ImmunityBio Inc Ordinary Shares | 5.11% |
| 2 | IOVA | Iovance Biotherapeutics Inc | 2.99% |
| 3 | NVAX | Novavax Inc | 2.68% |
| 4 | MRNA | Moderna Inc | 2.57% |
| 5 | KALV | KalVista Pharmaceuticals Inc | 2.55% |
| 6 | AXSM | Axsome Therapeutics Inc | 2.54% |
| 7 | MIRM | Mirum Pharmaceuticals Inc | 2.50% |
| 8 | ROIV | Roivant Sciences Ltd Ordinary Shares | 2.18% |
| 9 | TVTX | Travere Therapeutics Inc Ordinary Shares | 2.17% |
| 10 | KRYS | Krystal Biotech Inc | 2.03% |
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.
Inception Date: 2014-12-16